AcouSort: invites to a live broadcasted press conference due to publication of year-end report
AcouSort invites to a live broadcasted press conference on Thursday 25 February at 11.15. During the press conference, AcouSort's CEO Torsten Freltoft will review the company's development in 2020 and look ahead.
The press conference is arranged by Pressträff Direkt and will be held on Thursday 25 February at 11.15. Pressträff Direkt is a service provided by Laika Consulting in collaboration with Direkt Studios, part of Nyhetsbyrån Direkt. The live broadcast will be broadcast on Direkt Studio's Youtube channel:
During the press conference, there is an opportunity to ask questions to the company in the broadcast's comment field. Questions can also be emailed in advance to: mats.jonsson@laika.se mailto: mats.jonsson@laika.se.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.